Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure

Journal of Endocrinological Investigation

Volumn 33, Issue 8, 2010, Pages 554-558

  Feola, M ^a   Valeri, L ^b   Menditto, E ^a   Nervo, E ^a   Bianco, F ^c   Aspromonte, N ^d   Valle, R ^e   Visconti, G ^c  

^a Ospedale 4   (Italy)

^b Ospedale SS Annunziata   (Italy)

^c S Croce e Carle City Hospital   (Italy)

^d SPIRITO SANTO HOSPITAL   (Italy)

^e Ospedale Civile   (Italy)

Author keywords

Brain natriuretic peptide; Congestive heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE TEST; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ECHOCARDIOGRAPHY; FEMALE; FLUOROIMMUNOASSAY; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 78049389362     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6865     Document Type: Article

References (26)

1. de Lemos JA, McGuire DK, Drazner MH. B-Type natriuretic peptide in cardiovascular disease. Lancet 2003, 362: 316-22.
2. Richards AM, Lainchbury JG, Nicholls MG, Cameron AV, Yandle TG. Dendroaspis natriuretic peptide: endogenous or dubious? Lancet 2002, 359: 5-6.
3. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001, 39: 571-88.
4. Maisel A. B-Type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 2001, 7: 183-93.
5. Clerico A. Pathofisiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease? Clin Chem Lab Med 2002, 40: 752-60.
6. Feola M, Aspromonte N, Canali C, et al. Prognostic value of plasma brain natriuretic peptide, urea nitrogen and creatinine in outpatients >70 years of age with heart failure. Am J Cardiol 2005, 96: 705-9. (Pubitemid 41207318)
7. Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 2005, 11: 498-503. (Pubitemid 41403272)
8. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA 2002, 288: 1252-9.
9. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B-Type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002, 87: 131-5.
10. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001, 38: 1934-41.
11. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recording. Circulation 2002, 105: 595-601. (Pubitemid 34123434)
12. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea. J Am Coll Cardiol 2002, 39: 202-9. (Pubitemid 34084622)
13. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000, 46: 1529-34.
14. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison to N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosis left ventricular dysfunction. Clin Chim Acta 2001, 310: 193-7.
15. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 2003, 49: 1552-4. (Pubitemid 37011754)
16. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999, 10: 537-40.
17. Clerico A, Iervasi G, Del Chicca MG, et al. Analytical performance and clinical usefulness of a commercially available IRMA kit for the measurement of atrial natriuretic peptide in patients with heart failure. Clin Chem 1996, 42: 1627-33.
18. Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998, 21: 170-9.
19. Del Ry S, Clerico A, Giannessi D, et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of and IRMA method. Scand J Clin Lab Invest 2000, 60: 81-90. (Pubitemid 30202962)
20. Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001, 22: 1527-60.
21. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2: 358-67.
22. Fischer Y, Filzmaier K, Stiegler H, et al. Evaluation of a new, rapid test for quantitative determination of B-Type natriuretic peptide. Clin Chem 2001, 47: 591-4.
23. Baumgartner H. Neurohormones in valvular heart disease: what can they tell us? Eur Heart J 2008, 29: 290-2.
24. Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic Mitral regurgitation. Determinants and impact on outcome. Circulation 2005, 111: 2391-7.
25. Kerr AJ, Raffel OC, Whalley GA, Zeng I, Stewart RA. Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. Eur Heart J 2008, 29: 363-70.
26. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic in screening for left ventricular systolic dysfunction in general population. J Am Coll Cardiol 2003, 41: 113-20.